MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, received a drug license suspension order from the Assistant Director, Drugs Control Administration, Rangareddy, Telangana.

Regulatory Action Details

The suspension order targets a specific store operated by the subsidiary in Kuntloor, Telangana. The regulatory action was initiated under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

The company has quantified the potential financial impact of this regulatory action. MedPlus estimates a potential revenue loss of Rs 0.42 lacs due to the one-day suspension of the drug license for the affected store.

Compliance Disclosure

This disclosure was made under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, in its regulatory filing.

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on the BSE and NSE websites. Company Secretary & Compliance Officer Manoj Kumar Srivastava signed the disclosure on February 28, 2026.

MedPlus Health Services Limited has disclosed another regulatory action against its subsidiary, with a new drug license suspension order received from Andhra Pradesh authorities. This latest development adds to the company's ongoing regulatory challenges across multiple states.

Latest Andhra Pradesh Suspension

Optival Health Solutions Private Limited, a subsidiary of MedPlus Health Services, received a suspension order from the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Nagarampalem Guntur, Guntur District, Andhra Pradesh. The order was received on February 25, 2026, for violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Previous Regulatory Actions

Earlier regulatory actions affected the subsidiary's operations in Karnataka and Telangana. The Karnataka suspensions involved stores in Vinobha Nagar and KSRTC Davanagere locations, while Telangana action targeted a store in Surya Nagar Colony Mallpur.

Cumulative Impact Analysis

With the addition of the Andhra Pradesh suspension, the total regulatory impact on MedPlus Health Services subsidiary has expanded significantly across three states.

Regulatory Compliance

The disclosure was made under SEBI Regulation 30 in accordance with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The information has been made available on the company's website at www.medplusindia.com and will be accessible on BSE and NSE websites.

Corporate Communication

The regulatory filing was signed by Manoj Kumar Srivastava, Company Secretary and Compliance Officer of MedPlus Health Services Limited, on February 26, 2026. The communication was addressed to both BSE Limited and National Stock Exchange of India Limited as part of the company's listing obligations.